

A Registered Branch of the ESC



Application for the following position in

the EHRA Board: Treasurer



1. Your Identity

Title: Prof., MD, PhD, FESC

Family Name(s): Raatikainen

First Name(s): Matti Jukka Pekka

Birth Date: April 3, 1963

Type of address: Business Institute/Organisation:

University of Eastern Finland and Central Finland Heath Care District

Department:

Internal Medicine, Division of Cardiology

Address: Keskussairaalantie 19

Post Code/Zip: FI-40620
City: Jyväskylä
Country: Finland

Mobile Phone: +358503169001

Phone: +35814269911

Fax: +



A Registered Branch of the ESC



2. General Curriculum Vitae (300 words max) MJ PEKKA RAATIKAINEN, MD, PHD, FESC

DATE OF BIRTH: Haapavesi, Finland, April 3, 1963

EDUCATION AND ACADEMIC APPOINTMENTS

Professor of Medicine (2014-present), University of Eastern Finland

Professor of Cardiology (2010-2012), University of Tampere

Adjunct Professor (1998-present), University of Oulu

Special Competence in Medical Education (2011), Finnish Medical Association

eMBA (HRM), University of Oulu, expected May 2015

Internal Medicine Specialist (2000), Cardiologist (2001), University of Oulu

Postdoctoral Fellow (1994-96), University of Florida, USA

PhD (1993) and MD (1990), University of Oulu

HONORS AND AWARDS

Fellow of the European Society of Cardiology, 2010

Gold Medal of the Finnish Cardiac Society (FCS), 2014

Silver Medal of the FCS, 2009

Several prices for educational and professional achievements

ACADEMIC AND CLINICAL ADVISING

Several candidates supervised for PhD thesis

Several fellows from Finland and abroad supervised for clinical EP

Reviewer of many professorship, docent and doctoral thesis in Finland, Sweden and Norway

Regular referee for many peer reviewed journals including Eur Heart J, Europace, Heart

Rhythm, Circulation Arrhythmia and EP, Int J Cardiol, Annals of Medicine

Editorial Board Member "Sydänääni" (official journal of the FCS) 2004-2014

COMMITTEE APPOINTMENTS

For experience in ESC, EHRA and FCS see below

Ministry of Social Affairs and Health

Common Criteria for Elective Therapies WG Member, 2005-

National Institute for Health and Welfare

Medical Procedure Codes Development WG Member, 2005-

National Supervisory Authority for Welfare and Health

Permanent Medical Advisor, 2009-

Chairman of the National Atrial Fibrillation Guideline Committee 2004-present

Finnish Heart Association

Medical Advisory Board Member 2008-2014

Nordic Electrophysiology Fellowship Grant Board 2004-present

MAJOR CLINICAL AND RESEARCH INTEREST

Cardiac arrhythmias, clinical electrophysiology and device therapies

BIBLIOGRAPHY

More than 100 original and review articles including several EHRA position papers and EHRA White Book in peer reviewed journals. Editor of several medical books and internet-based learning tools. About 100 chapters in national and international medical books.



A Registered Branch of the ESC



3. Previous experience(s) in the EHRA or ESC or your National Bodies?

European Society of Cardiology (ESC)

Credentials Committee Member, 2011-

ESC Congress Abstract Reviewing Committee Member, 2010–

Official Onsite Reporter/Spoke Person in the ESC Congress 2008, 2010, 2011

Guidelines for Management of Atrial Fibrillation, reviewer 2010

European Hearth Rhythm Association (EHRA)

Scientific Documents Committee Member, 2009-2011

Training Fellows Committee Member, 2011-present

EHRA White Book Subcommittee Chairman, 2013-present

UEMS Cardiology Section

Representative for Finland, 2010-13

Vice President for Nordica and Baltic countries, 2013-present

The Finnish Cardiac Society Board 2004-2014

Past President 2012-2014

President, 2010-2012

President Elect, 2008-2010

Treasurer, 2004-2008

National ESC Guideline Coordinator 2012-2014

Working Group of Cardiac Arrhythmias and Pacing of the FCS

Chairman 2007-2010

Secretary 2003-2007

Finnish Heart Association

Medical Advisory Board Member 2008-2014



A Registered Branch of the ESC



4. Why are you interested in joining the EHRA Board (150 words max)?

The work in the EHRA Board would be a natural continuity to my previous work in the Finnish Cardiac Society Board and in the ESC and EHRA committees. Hence, I think that it is time for me to take the next step and dedicate my time and expertise to the EHRA Board. As a Treasurer I would like to continue the invaluable work of my predecessors and help EHRA to achieve its mission "To improve the quality of life of the European population by reducing the impact of cardiac arrhythmias and reduce sudden cardiac death". EHRA has done tremendous work by providing training for fellows, and arranging educational activities and certification programs. I am sure that due to my prior experience I would be a great asset while EHRA continues to improve and homogenize management of cardiac arrhythmias and possibly also to take more active role in arrhythmia research.

5. How will you coordinate your EHRA appointment with your daily clinical/research workload?

I finished my term in the FCS Board about a year ago. Therefore, I can now dedicate a significant proportion of my time to the EHRA. Due to long experience with work in professional medical associations I am used to share my time between different tasks and also to work in the evenings and weekends. In addition, the hospital and university have always encouraged me to participate in the work of professional associations and given me an opportunity to participate in the meetings of the associations.



A Registered Branch of the ESC



6. Please list your conflit of interest

A/Direct personal payments (speaker fees, honoraria, advisory board fees, consultancy, investigator...)

Company (one company): Bayer

Product or therapeutic area: Oral anticoagulation

X <10 K€ per year / O 10-50 K€ per year / O50-100 K€ per year/ O >100 >K€ per year

Company (one company): Boehringer Ingelheim Product or therapeutic area: Oral anticoagulation

X <10 K€ per year / O 10-50 K€ per year / O50-100 K€ per year/ O >100 >K€ per year

Company (one company): BMS/Pfizer

Product or therapeutic area: Oral anticoagulation

X <10 K€ per year / O 10-50 K€ per year / O50-100 K€ per year/ O >100 > K€ per year

Company (one company): Biosense Webster

Product or therapeutic area: Cardiac arrhythmia therapies

X <10 K€ per year / O 10-50 K€ per year / O50-100 K€ per year/ O >100 > K€ per year

Company (one company): Meda Pharma

Product or therapeutic area: Cardiac arrhythmia therapies

X <10 K€ per year / O 10-50 K€ per year / O50-100 K€ per year/ O >100 > K€ per year

Company (one company): St Jude Medical

Product or therapeutic area: Cardiac arrhythmia therapies

X <10 K€ per year / O 10-50 K€ per year / O50-100 K€ per year/ O >100 >K€ per year

B/ payments to your institution (speaker fees, honoraria, advisory board fees, consultancy, investigator...)

Company (one company): Bayer (investigator in a multicenter trial)

Product or therapeutic area: Oral anticoagulation

X <10 K€ per year / O 10-50 K€ per year / O50-100 K€ per year/ O >100 > K€ per year

C/receipts of royalties for intellectual property

Nothing to declare

D/ research funding (departmental or institutional)

Company (one company): St Jude Medical (primary investigator for a multicenter trials)

Product or therapeutic area: Cardiac arrhythmia therapies

X <10 K€ per year / O 10-50 K€ per year / O50-100 K€ per year/ O >100 > K€ per year

Company (one company): Thrombosis Research Institute (national coordinator in an international registry)

Product or therapeutic area: Oral anticoagulation

 $X < 10 \text{ K} \in \text{ per year } / \text{O} = 10-50 \text{ K} \in \text{ per year } / \text{O} = 100 \text{ K} \in \text{ per year } / \text{O} = 100 \text{ k} \times \text{ per year } / \text{O} = 100 \text{ k} \times \text{ per year } / \text{O} = 100 \text{ k} \times \text{ per year } / \text{O} = 100 \text{ k} \times \text{ per year } / \text{O} = 100 \text{ k} \times \text{ per year } / \text{O} = 100 \text{ k$

Product or therapeutic area: Cardiac arrhythmia therapies

O <10 K€ per year / O 10-50 K€ per year / X O 50-100 K€ per year / O >100 > K€ per year

E/ research funding (personal)

Nothing to declare

Position of influence declaration:

1/Direct substantial shareholding or direct financial interst in healthcare, media, education companies or companies in relationship (suppliersà or in competition with ESC or in contradiction with ESC mission 2/Employement in healthcare institution (part time or full time)

3/Membership or affliation in political/pressue group associations related to the field of cardiology

4/ Any potential interest to be declared related to the currency position to be held

Nothing to declare